Short answer
Viatris (VTRS) filed its fiscal 2024 10-K annual report with the SEC on Feb 27, 2025. It reported revenue of $14.7B (−4.5% year over year) and net income of −$634M.
- Top risk flagged: FDA warning letter and import alert on Indore, India facility, blocking 11 products from U.S., 2025 revenue impact approx. $500M, earnings impact $385M
FY2024 key financial metrics · XBRL
- Revenue
- $14.7B
- −4.5% YoY
- Net income
- −$634M
- −1259.4% YoY
- Operating margin
- 0.1%
- −4.9 pp YoY
- Gross margin
- 38.3%
- −3.6 pp YoY
- EPS (diluted)
- −$0.53
- −1160.0% YoY
- ROE
- -3.4%
- −3.7 pp YoY
- Operating cash flow
- $2.3B
- −17.7% YoY
Source: XBRL data from the Viatris (VTRS) FY2024 10-K on SEC EDGAR. USD.
Viatris FY2024 10-K analysis
AI summary of each section, grounded in the filing text
Business Overview
- Core business model focused on pharmaceutical manufacturing, supply chain, and commercial operations with continued divestiture activity
- Recent divestitures include Biocon Biologics Transaction, OTC products, women’s healthcare, and API business segments emphasized this year
- Strategic shift driven by multiple high-profile divestitures resulting in reduced total revenues and cash flows versus prior year
- Equity consideration from Biocon Biologics valued at approx. $1.3 billion on balance sheet as of Dec 31, 2024, with downside protection but limited liquidity
- New risks from transition service obligations and indemnification agreements increasing operational exposure and potential financial liabilities
Management Discussion & Analysis
- Forward-looking outlook or guidance not mentioned in excerpt
- Focus solely on explaining use and reconciliation of non-GAAP financial measures
Risk Factors
- FDA warning letter and import alert on Indore, India facility, blocking 11 products from U.S., 2025 revenue impact approx. $500M, earnings impact $385M
- Exposure to geopolitical conflicts including Russia-Ukraine and Middle East impacting supply chains and economic conditions in Emerging Markets
- Dependency on Lexicon for clinical and commercial supply of sotagliflozin outside U.S. and Europe under new licensing agreement with upfront $25M payment
- Competitive risk from generic entry of Amitiza® 24 μg in Japan in December 2025 after patent expiry
- High development cost and milestone payments up to $2.75B for Idorsia Phase 3 assets with regulatory and clinical trial uncertainties
Generated from the filing text; verify against the original. How to read a 10-K
Other Viatris annual reports
Ask about this 10-K
Compare years, dig into a risk factor or check the numbers against insider trades and fund holders.